Table 2.

Absolute Effect of Treatment with Pravastatin on Cardiovascular Outcomes and Mortality After 3.2 Years According to Homocysteine Level

	Placebo		Pravastatin		ARR (95% CI)	Difference in ARR (vs Low) (95% CI)	P-Valueb
Outcomes and Homocysteine Groupsa	n	Cumulative Incidence of Events,% (95% CI)	n	Cumulative Incidence of Events,% (95% CI)
Fatal and nonfatal CHD
Low	48	8.2 (6.0–10.5)	32	6.7 (4.5–8.9)	1.6 (−1.6–4.7)	Reference
Medium	54	9.9 (7.4–12.4)	47	8.7 (6.3–11.0)	1.2 (−2.2–4.7)	−0.32 (−5.0–4.3)	.89
High	76	15.9 (12.8–19.1)	47	9.2 (6.7–11.7)	6.7 (2.7–10.7)	5.2 (0.11–10.3)	.046
Nonfatal MI
Low	29	5.1 (3.3–6.9)	26	5.6 (3.6–7.7)	−0.5 (−3.2–2.2)	Reference
Medium	39	7.3 (5.1–9.5)	26	5.1 (3.2–7.0)	2.2 (−0.73–5.0)	2.7 (−1.3–6.7)	.18
High	51	11.3 (8.5–14.1)	32	6.4 (4.3–8.5)	4.9 (1.4–8.4)	5.5 (1.0–9.9)	.02
CHD mortality
Low	20	3.4 (1.9–4.9)	11	2.0 (0.83–3.2)	1.4 (–0.45–3.3)	Reference
Medium	18	3.3 (1.8–4.7)	27	4.7 (3.0–6.4)	−1.5 (−3.7–0.83)	−2.9 (−5.8–0.08)	.06
High	33	6.5 (4.4–8.6)	18	3.5 (1.9–5.1)	3.0 (0.35–5.6)	1.5 (−1.7–4.8)	.35
Non-CHD mortality
Low	25	4.8 (3.0–6.6)	31	6.9 (4.6–9.1)	−2.1 (−4.9–0.84)	Reference
Medium	30	5.4 (3.5–7.3)	32	5.9 (3.9–7.8)	−0.46 (−3.2–2.3)	1.6 (−2.4–5.6)	.43
High	46	8.4 (6.1–10.7)	34	6.5 (4.4–8.5)	2.0 (−1.2–5.1)	4.0 (−0.24–8.2)	.06
All-cause mortality
Low	45	8.0 (5.8–10.3)	42	8.7 (6.3–11.1)	−0.66 (−4.0–2.7)	Reference
Medium	48	8.5 (6.2–10.8)	59	10.3 (7.8–12.8)	−1.8 (−5.2–1.6)	−1.1 (−5.9–3.6)	.64
High	79	14.3 (11.4–17.2)	52	9.8 (7.3–12.2)	4.6 (0.78–8.4)	5.2 (0.19–10.3)	.04

CI = confidence interval; CHD = coronary heart disease.

^aGroup sizes: low: placebo n = 597, pravastatin n = 575; medium: placebo n = 579, pravastatin n = 598; high: placebo n = 588, pravastatin n = 585.

^bP-value of difference in absolute risk reduction (ARR) compared with reference group low homocysteine estimated using z-test.